(Q40281727)

19 September 2017

title

Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan (English)

1 reference

19 September 2017

1 reference

7

Kiminori Fujimoto

1 reference

19 September 2017

author name string

Yuka Horiuchi-Yamamoto

1

1 reference

19 September 2017

Akihiko Gemma

2

1 reference

19 September 2017

Hiroyuki Taniguchi

3

1 reference

19 September 2017

Yoshikazu Inoue

4

1 reference

19 September 2017

Fumikazu Sakai

5

1 reference

19 September 2017

Takeshi Johkoh

6

1 reference

19 September 2017

Shoji Kudoh

8

1 reference

19 September 2017

publication date

30 June 2012

1 reference

International Journal of Clinical Oncology

19 September 2017

published in

1 reference

19 September 2017

volume

18

1 reference

19 September 2017

issue

4

1 reference

19 September 2017

page(s)

743-749

1 reference

https://scigraph.springernature.com/pub.10.1007/s10147-012-0438-0

19 September 2017

exact match

0 references

cites work

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Diagnosis and management of drug-associated interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Clarification of clinical features of interstitial lung disease induced by irinotecan based on postmarketing surveillance data and spontaneous reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Drug-induced interstitial lung diseases associated with molecular-targeted anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Pulmonary drug toxicity: radiologic and pathologic manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Drug-induced pneumonitis: thin-section CT findings in 60 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Hyperoxia-induced diffuse alveolar damage in pigs: correlation between thin-section CT and histopathologic findings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Hepatitis C virus and the lung: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10147-012-0438-0

Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22752255

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Drug-induced lung disease: high-resolution CT and histological findings

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22752255

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

1 reference

https://pubmed.ncbi.nlm.nih.gov/22752255

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10147-012-0438-0

1 reference

Dimensions Publication ID

19 September 2017

1048627743

0 references

1 reference